Shanghai Fosun Pharmaceutical (Group) Co. Ltd. held the 2026 first extraordinary general meeting, the 2026 first A shareholders’ class meeting and the 2026 first H shareholders’ class meeting on 27 February 2026. Shareholders approved proposals related to the spin-off of Fosun Adgenvax for an initial public offering of H shares and listing on the Main Board of the Hong Kong Stock Exchange, including the spin-off plan and proposal, the purpose and feasibility of the spin-off, maintenance of Shanghai Fosun Pharmaceutical’s independence and continuous operating capability, Fosun Adgenvax’s standardized operations capability, safeguarding shareholder and creditor interests, completeness and validity of procedures and documents, shareholdings of certain directors and senior management and affiliated parties in the company to be spun off, authorisation for the board to handle matters related to the spin-off, and the proposed assured entitlements to H shareholders in connection with the spin-off. At the A shareholders’ class meeting, the proposal on providing assured entitlements to H shareholders in connection with the spin-off was not approved. At the H shareholders’ class meeting, the same proposal was approved.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260227-12032860), on February 27, 2026, and is solely responsible for the information contained therein.
Comments